VELMENI Secures FDA 510(k) for AI-Powered 3D CBCT Imaging
SUNNYVALE, Calif., July 23, 2026 VELMENI AI has received U.S. Food and Drug Administration (FDA) 510(k) clearance for VELMENI...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SUNNYVALE, Calif., July 23, 2026 VELMENI AI has received U.S. Food and Drug Administration (FDA) 510(k) clearance for VELMENI...
SARASOTA, Fla., July 14, 2026 Silo Pharma announced that its wholly owned subsidiary, QwikAgents, has been accepted into AMD’s...
NEW YORK, June 25, 2026 Aidoc announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device...
